What is it?
What bromantane is
1Bromantane is a synthetic adamantane derivative sold or discussed under the name Ladasten in Russian clinical literature. It is not a botanical or nutrient; the evidence base is closer to a research and drug-development compound than a typical dietary supplement ingredient.
Evidence snapshot
3The main clinical studies evaluated Ladasten in people with asthenic or A nervous-exhaustion term used for physical and mental fatigue.Source symptoms. One randomized blinded report found an advantage over placebo, while the larger multicenter study had no comparator. Neither establishes broad healthy-user cognition, neuroprotection or athletic performance.
Study dose and label dose differ
10The clinical study range differs from the daily regimen in the historical Russian tablet instructions. Neither establishes an optimal dose, cycle or long-term schedule for consumer capsules or powders.
Names, aliases and forms
Mechanisms of action
Dopaminergic and catecholamine pathways
5Animal work suggests ladasten can influence dopamine-related pathways, including tyrosine hydroxylase expression and dopamine/L-DOPA measures in brain regions studied in rats. This supports a plausible stimulant-like mechanism, but it does not prove the same magnitude or outcome in humans.
Synaptic plasticity signal
5In rat hippocampal preparations, ladasten affected short-term and long-term potentiation markers through protein-synthesis and dopamine-dependent mechanisms. This is mechanistic context only, not proof that bromantane improves memory or learning in people.
Potential effects and evidence map
Russian Ladasten studies describe fatigue and wellbeing outcomes in selected clinical populations. Small healthy-volunteer reports are mixed and do not establish everyday cognitive enhancement. Animal dopamine and synaptic findings explain research interest rather than a proven human benefit.
A reliable mental-energy benefit magnitude in healthy adults is not established. Selected Russian clinical studies and small fatigued-volunteer reports cannot define an everyday consumer effect.
A reliable relaxation benefit in healthy adults is not established. Patient studies describe calming-related observations in clinical populations.
A reliable mood or wellbeing benefit in healthy adults is not established. Short clinical studies evaluated quality-of-life outcomes in selected patients.
Typical dosages and timing
The multicenter study used the displayed daily range for 28 days in a clinical population. It is study context rather than an established healthy-user supplement regimen.
Patients were assessed during a four-week course and again one month after it ended. The course length does not establish an optimal cycle.
Timing & effect horizon
The uncontrolled multicenter study first assessed patients on day 3 and reported an antiasthenic signal then. This is not a measured hour-by-hour onset in healthy consumers.
Historical Russian tablet information reports a plasma concentration peak at 2-4 hours. Plasma peak timing does not establish subjective onset.
Historical Russian tablet information reports a The time for blood levels to fall by half during the final elimination phase.Source of 11.21 hours, rounded here to about 11 hours. Half-life describes elimination rather than the duration of a cognitive or subjective effect.
Patients in the multicenter study were reassessed one month after the course ended. Follow-up observation cannot define the duration of a single dose.
Urinary metabolite detection concerns exposure and anti-doping testing. It cannot define a safe competition washout interval or a period of subjective benefit.
The clinical day-3 signal, plasma peak and elimination half-life measure different things. The sources do not establish a reliable single-dose benefit duration or an evidence-based consumer cycle.
Safety, side effects and risk profile
Russian Ladasten product information lists excessive activation and difficulty falling asleep; allergic reactions are also possible. Their frequency in healthy consumers is not quantified.
Cardiovascular and sympathetic-adrenal effects were measured in rats and cats. These findings do not quantify a cardiovascular hazard at ordinary human oral exposure.
The Russian product information reports reduced thiopental hypnotic action. Broader stimulant or dopaminergic combinations lack adequate direct human interaction evidence.
Human pregnancy and lactation safety are unestablished; animal reproductive and offspring-development findings provide a targeted caution rather than an adult base-risk estimate.
A short placebo-controlled study reported no withdrawal syndrome after a 28-day course. This cannot establish absence of dependence with prolonged or different use.
Under the WADA 2026 List, bromantan is prohibited in competition in S6.A. This classification does not determine national sale, import or possession law.
Short clinical and small laboratory reports cannot calibrate a reliable numeric safety estimate for generally healthy adults, prolonged use or consumer products. Unknown does not mean safe.
The 728-patient multicenter analysis reported adverse effects in 3%, discontinuation in 0.8% and no serious adverse effects. This short, uncontrolled clinical dataset cannot exclude uncommon harms or establish long-term consumer safety.
Rat toxicology work reported stimulation at lower experimental doses and suppressed activity, autonomic signs, and gastrointestinal effects at much higher doses. Animal dose levels do not translate directly to human dosing.
Animal reproductive/development research reported changes in litter size, survival, and development measures after bromantan exposure. Human pregnancy and lactation safety data are not established.
Interactions and cautions
Rat dopamine-pathway findings make additive activation with stimulants or dopaminergic compounds plausible, but they do not establish specific human interaction rates or a safe stacking schedule.
Russian product information reports reduced thiopental hypnotic action and preserved benzodiazepine anxiolytic action. That limited statement does not establish that sedative, psychiatric or neurologic drug combinations are safe.
Legal and regulatory status
Under the WADA 2026 Prohibited List, bromantan is a non-Specified stimulant in S6.A and is prohibited in competition. Anti-doping rules and national medicine or supplement law are separate questions.
As of October 2026, the U.S. FDA Substance Registration System identifies bromantane as UNII N1ILS53XWK. FDA explicitly states that UNII availability does not imply regulatory review or approval. This identity record cannot establish lawful supplement marketing, importability or medicine approval in the U.S. or other markets.
Practical buying and quality notes
- Compare capsule count and labeled bromantane milligrams per capsule. For a comparable mass, multiply capsules by milligrams per capsule and divide by 1,000 to obtain grams; include shipping and currency. Capsule price alone cannot compare different strengths or powders.
- Look for batch-specific identity and purity testing that identifies bromantane and matches the product lot. A certificate cannot establish cognitive efficacy, and clinical Ladasten reports do not verify a retailer product.2
- For WADA-governed athletes in 2026, the label description "nootropic" or "supplement" does not exempt bromantan from its in-competition stimulant prohibition.9
FAQ
Do healthy-volunteer studies show better cognition?
13A small 2009 laboratory report described changes during mental fatigue after a single dose. Its abstract omits enrollment and numerical effect sizes, so it cannot establish a dependable everyday cognitive benefit.
Were there null findings in healthy volunteers?
14Yes. A placebo-comparison report in ten healthy volunteers found no change in subjective state or principal performance components in unfatigued men, despite EEG changes. Brain-recording changes are not equivalent to better cognition.
What bromantane dosage has been studied?
2The compact dosage field shows the daily range in the multicenter clinical study. The participants and four-week exposure differ from ordinary healthy-user use; the study does not establish a personalized regimen.
Is bromantane allowed for athletes?
9Under WADA rules in 2026, bromantan is prohibited in competition in S6.A. A product listing does not establish anti-doping permission or national legal status.
What is known about duration and cycles?
2Clinical reports used short courses, with one-month follow-up in the multicenter study. Those observations do not establish an optimal consumer cycle, a safe washout period or long-term safety.
References
- PubChem Compound Summary for CID 4660557, Bromantane. National Center for Biotechnology Information.
- Voznesenskaia TG, Fokina NM, Iakhno NN. Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(5 Pt 1):17-26. PMID: 21322821.
- Neznamov GG, Siuniakov SA, Teleshova SE, et al. Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia: results of the comparative clinical study with placebo. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(5):20-26. PMID: 19491814.
- Siuniakov SA, Grishin SA, Teleshova ES, Neznamov GG, Seredenin SB. Pilot clinical trial of ladasten. Eksp Klin Farmakol. 2006;69(4):10-15. PMID: 16995430.
- Mikhaylova M, Vakhitova JV, Yamidanov RS, Salimgareeva MKh, Seredenin SB, Behnisch T. The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats. Neuropharmacology. 2007;53(5):601-608. doi:10.1016/j.neuropharm.2007.07.001. PMID: 17854844.
- Iezhitsa IN, Spasov AA, Bugaeva LI, Morozov IS. Toxic effect of single treatment with bromantane on neurological status of experimental animals. Bull Exp Biol Med. 2002;133(4):380-383. doi:10.1023/a:1016206306875. PMID: 12124651.
- Iezhitsa IN, Spasov AA, Bugaeva LI. Effects of bromantan on offspring maturation and development of reflexes. Neurotoxicol Teratol. 2001;23(2):213-222. doi:10.1016/S0892-0362(01)00119-2. PMID: 11348840.
- Morozov IS, Efimova LP, Kryzhanovskii SA. The effect of bromantane on the cardiovascular and sympathetic-adrenal systems in animals. Eksp Klin Farmakol. 2000;63(1):33-36. PMID: 10763107.
- World Anti-Doping Agency. 2026 Prohibited List, S6.A non-Specified stimulants: Bromantan. Effective 1 January 2026.
- Ladasten medical-use instructions reproduced by Medi.ru. Dated 3 May 2015; accessed October 2026.
- Oliynyk S, Oh S. The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance. Biomolecules & Therapeutics. 2012;20(5):446-456.
- U.S. Food and Drug Administration. Substance Registration System: Bromantane, UNII N1ILS53XWK. Accessed October 2026.
- Bogdan NG, Kolotilinskaia NV, Iarkova MA, et al. Effect of ladasten on the psychophysiological parameters of healthy volunteers. Eksp Klin Farmakol. 2009;72(3):3-9. PMID: 19642584.
- Viatleva OA, Barchukov VG, Morozov IS, et al. The neuro- and psychophysiological effects of bromantane. Voen Med Zh. 2000;321(8):61-65,96. PMID: 10998997.